Healthpeak Properties Inc. Common Stock vs Novavax Inc — how do they compare? Healthpeak Properties Inc. Common Stock trades at $18.55 (market cap $12.87B), while Novavax Inc trades at $11.11 (market cap $1.85B). The key difference: Healthpeak Properties Inc. Common Stock is far larger — about 7× Novavax Inc's market cap, and Healthpeak Properties Inc. Common Stock pays a 6.54% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Healthpeak Properties Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| DOC | NVAX | |
|---|---|---|
Market Cap | $12.87B | $1.85B |
Volume | 5,134,919 | 8,362,562 |
Sector | Real Estate | Health |
52-Week High | $22.82 | $12.56 |
52-Week Low | $15.78 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $21.56B | $1.43B |
Dividend Yield | 6.54% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Healthpeak Properties is a healthcare real estate investment trust in the United States. It owns, operates, and develops outpatient medical, laboratory, and senior housing properties.
Read more on DOC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →